GVS completed the acquisition of the whole blood business of Haemonetics for up to $67.8m.

GVS, a company specializing in advanced filtration solutions, completed the acquisition of the whole blood business of Haemonetics Corporation, a global healthcare company specializing in blood and plasma management solutions for $67.8m. “Following the acquisition of STT and Haemotronic, this transaction marks another step in our expansion strategy in the transfusion medicine market, that sees today only one player with a fully vertical business model. With Haemonetics’ business, GVS becomes a global and fully vertically integrated actor, adding complementary and highly synergic assets to its existing product offering and further reinforcing its leadership in the Healthcare filtration sector,” Massimo Scagliarini, GVS CEO.